Senior Credit Analyst, Lucror Analytics

Trung Nguyen

Senior Credit Analyst

High Yield Experts

Lucror Analytics

Lucror Analytics is a leading credit and ESG research specialist and a provider of technology solutions for differentiated fixed income strategies. Our roots are in bottom-up fundamental credit analysis with a specialization in high yield corporate credits from Europe, Asia and Latin America. We are one of few research specialists integrating ESG considerations with fundamental credit research through a dedicated ESG platform. Our ESG assessment covers five key criteria: Disclosure, E,S, & G Pillars, Controversies, ESG Impact on Credit and ESG Momentum.

Recognizing the importance and value-add of Factor Investing in fixed income, Lucror developed the Smart Quant Navigator (SQN), an intuitive platform that helps clients devise and implement factor-based strategies ranging from pure quant to active fundamental, with integrated ESG.

Our company has been at the forefront of developments in the fixed income markets, identifying opportunities and consistently delivering new products and value-adding solutions to clients. Lucror has close relationships with the largest and most reputable asset managers, family offices, hedge funds, investment and wealth managers globally.

Credit

<ul>
<li>Biocon Biologics' (BBL) and Biocon Limited's (BL) Q2/24-25 results (the first release after the USD notes issuance) were slightly weaker than expected, with lower than forecast growth and earnings.</li>
<li>Leverage appears high at the BBL level, but seems better at BL's level.</li>
<li>Liquidity appears weak, albeit this is offset by BL's large stakes in listed companies.</li>
</ul>


Biocon Biologics' (BBL) and Biocon Limited's (BL) Q2/24-25 results (the first release after the USD notes issuance) were slightly weaker than expected, with lower than forecast growth and earnings.
Leverage appears high at the BBL level, but seems better at BL's level.
Liquidity appears weak, albeit this is offset by BL's large stakes in listed companies.


Biocon Biologics - Earnings Flash - Q2 FY 2024-25 Results - Lucror Analytics

India

Biocon Biologics India Limited of India operates as a biopharmaceutical company. The Company offers prevention, alleviation, and treatment for chronic diseases such as diabetes, oncology, cancer, and autoimmune diseases. Biocon Biologics India serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocon Biologics India (1777628D IN)

Biocon Biologics - Earnings Flash - Q2 FY 2024-25 Results - Lucror Analytics

Biocon Biologics' (BBL) and Biocon Limited's (BL) Q2/24-25 results (the first release after the USD notes issuance) were slightly weaker than...

Lucror Analytics

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)